PPARG
ENSG00000132170
Target class
Nuclear receptor
Chromosome
3
Approved drugs
7
Clinical candidates (approved and in development)
36
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 36
- Chemical probe available
- Yes
- Target name
- PPARG
- Gene name
- Peroxisome proliferator activated receptor gamma
- Gene symbol
- PPARG
- Protein name
- Peroxisome proliferator-activated receptor gamma (PPAR-gamma) (Nuclear receptor subfamily 1 group C member 3)
- PPARG1
- PPARG2
- NR1C3
- PPARgamma
- Gene biotype
- Protein coding
- Gene family
- Peroxisome proliferator activated receptors
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 48
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 111.14
- Tissue specificity (Gini)
- 0.647
- Tissue specificity (tau)
- 0.914
- KEGG gene identifiers
- hsa:5468
- Protein interaction confidence
- 0.850071
- Protein interaction partners
- 168
- R-HSA-1989781
- R-HSA-381340
- R-HSA-383280
- R-HSA-4090294
- R-HSA-8943724
- R-HSA-9022707
- R-HSA-9844594
- End position
- 12434574
- Start position
- 12287368
- Chromosome
- 3
- Strand
- Forward
- Nucleus . Cytoplasm . Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner (PubMed:17101779). NOCT enhances its nuclear translocation (By similarity). .
- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus .
- Nucleoplasm
- Vesicles
- PubMed 17101779
- PubMed 23525231
- Tissue specificity (tau)
- 0.914286
- Expression inequality (Gini)
- 0.646805
Expression in transcripts per million
- Adipose - Subcutaneous
- 111.14
- Adipose - Visceral (Omentum)
- 100.82
- Breast - Mammary Tissue
- 71.26
- Colon - Transverse
- 21.58
- Cells - Cultured fibroblasts
- 20.42
Expression in transcripts per million
- Adipose - Subcutaneous111.14
- Adipose - Visceral (Omentum)100.82
- Breast - Mammary Tissue71.26
- Colon - Transverse21.58
- Cells - Cultured fibroblasts20.42
- Lung19.46
- Thyroid18.51
- Ovary17.47
- Bladder15.31
- Cervix - Ectocervix14.11
- Nerve - Tibial13.79
- Artery - Coronary11.62
- Spleen11.03
- Uterus10.76
- Stomach10.46
- Vagina9.38
- Small Intestine - Terminal Ileum9.24
- Cervix - Endocervix8.18
- Kidney - Medulla8.15
- Fallopian Tube7.9
- Kidney - Cortex7.85
- Testis7.02
- Skin - Sun Exposed (Lower leg)6.02
- Colon - Sigmoid5.92
- Prostate5.36
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0007584
- GO:0008217
- GO:0010628
- GO:0010629
- GO:0010745
- GO:0010875
- GO:0010887
- GO:0016525
- GO:0030224
- GO:0030509
- GO:0030512
- GO:0030514
- GO:0032376
- GO:0032869
- GO:0035357
- GO:0042593
- GO:0042789
- GO:0043409
- GO:0043537
- GO:0045087
- GO:0045668
- GO:0045834
- GO:0045893
- GO:0045944
And 19 more, listed on the interactive page.
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0043235
- GO:0090575
- GO:0000976
- GO:0000978
- GO:0001221
- GO:0001228
- GO:0003676
- GO:0003677
- GO:0003690
- GO:0003700
- GO:0004879
- GO:0004955
- GO:0005515
- GO:0008270
- GO:0019899
- GO:0042277
- GO:0042802
- GO:0043565
- GO:0046965
- GO:0050692
- GO:0050693
- GO:0050699
- GO:0051393
- GO:0070412
- GO:0097677
- GO:0140297
increased inflammation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased inflammation
- renal
- immune
- cardiovascular
PubMed 28216264increased heart weight
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart weight
- renal
- immune
- cardiovascular
PubMed 28216264heart failure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: heart failure
- renal
- immune
- cardiovascular
PubMed 28216264increased plasma volume
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased plasma volume
- renal
- immune
- cardiovascular
PubMed 28216264decreased inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased inflammation
- renal
- immune
- cardiovascular
PubMed 28216264increased body weight
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased body weight
- renal
- immune
- cardiovascular
PubMed 28216264decreased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased urinary sodium excretion
- renal
- immune
- cardiovascular
PubMed 28216264decreased platelet aggregation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased platelet aggregation
- renal
- immune
- cardiovascular
PubMed 28216264decreased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood glucose
- renal
- immune
- cardiovascular
PubMed 28216264decreased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased urine excretion
- renal
- immune
- cardiovascular
PubMed 28216264increased water retention
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased water retention
- renal
- immune
- cardiovascular
PubMed 28216264
receptor binding
Studies
- biochemical: NVS_NR_hPPARg, is one of one assay component(s) measured or calculated from the NVS_NR_hPPARg assay. It is designed to make measurements of fluorescent polarization, a form of binding reporter, as detected with fluorescence polarization signals by Fluorescence Polarization technology.
Biological samples
- cell-free
Evidence sourceregulation of transcription factor activity
- cell-based: ATG_PPARg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_PPRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: TOX21_PPARg_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity..
- cell-based: ATG_PPRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: TOX21_PPARg_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.
- HEK293, cell line
- HEK293T, cell line
- HepG2, cell line
Evidence sourceprotein stabilization
- cell-based: OT_PPARg_PPARgSRC1_0480, is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.
- cell-based: OT_PPARg_PPARgSRC1_1440, is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.
Biological samples
- HEK293T, cell line
Evidence source
Related records
Trials (1,509)
- "NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "Supracondylar Radial Nerve Block Guided by Ultrasound Versus Hematoma Block for Analgesic Management in Closed Reduction of Distal Radius Fractures"
- "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
- (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
- 11ß-HSD1 and Metabolic Syndrome
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
- A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
- A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis
- A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"
- A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults
- A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)
- A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
- A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
- A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients
- A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.
- A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)
Drugs (56)
- Aleglitazar Peroxisome proliferator-activated receptor gamma agonist
- Arhalofenate Peroxisome proliferator-activated receptor gamma modulator
- ATX08-001 Peroxisome proliferator-activated receptor gamma modulator
- AVE0847 Peroxisome proliferator-activated receptor gamma agonist
- Balaglitazone Peroxisome proliferator-activated receptor gamma partial agonist
- Balsalazide Peroxisome proliferator-activated receptor gamma agonist
- Balsalazide disodium Peroxisome proliferator-activated receptor gamma agonist
- Bardoxolone
- Bardoxolone methyl Peroxisome proliferator-activated receptor gamma antagonist
- Bexarotene
- Bezafibrate Peroxisome proliferator-activated receptor agonist
- Chiglitazar Peroxisome proliferator-activated receptor agonist
- Ciglitazone
- CLX-0921 Peroxisome proliferator-activated receptor gamma agonist
- DB959 Peroxisome proliferator-activated receptor gamma agonist
- Diclofenac
- Edaglitazone
- Efatutazone Peroxisome proliferator-activated receptor gamma agonist
- Efatutazone hydrochloride Peroxisome proliferator-activated receptor gamma agonist
- Elafibranor